The partnership will see IME employing its well-established platform technology for fabricating top-down silicon-based nanowire field-effect transistor (FET) sensors and FET nanoplate arrays designed by Illinois. The devices will be fabricated at IME’s 8-inch CMOS (Complementary metal–oxide–semiconductor) and MEMS (Micro-electro-mechanical Systems) fabrication facility. As a means of testing their performance, these devices will be used to detect cancer protein biomarkers, with an eye on eventually utilising them in point-of-care diagnostic systems — an area of application in which nanosensors are expected to have revolutionary ramifications.
“Despite the technological advances made to nanowire sensors in recent times, a number of critical unknowns remain, such as the influence of the surrounding environment and electrostatic screening on nanowire sensor performance,” said Dr. Chen Yu, principal investigator for IME’s Bioelectronics Programme. "Our collaboration with Illinois will seek to provide the answers to all the lingering questions about nanowire sensor design and fabrication that have thus far hindered the research community's attempts at achieving consistent and reproducible results."
“The interdisciplinary nature of cancer nanotechnology makes selecting a research partner a tenuous affair, as few R&D establishments possess the necessary breadth and depth of expertise and capabilities,” said Illinois’ principal investigator for this project, Professor Rashid Bashir from the Department of Electrical and Computer Engineering & Bioengineering. “IME came immediately to mind because of the field-leading research it conducts through its Bioelectronics Programme, as well as its world-class silicon fabrication process capabilities and staff of full-time researchers with industry-proven experience.”
“The pace of decentralisation in the healthcare industry has turned point-of-care diagnostics into one of the fastest-growing areas in healthcare today, a market expected to be worth over USD 22.5 billion in 2013[1],” said Professor Dim-Lee Kwong, Executive Director of IME. “The fact that nanoscale biosensors are increasingly viewed as pivotal components of point-of-care systems bears testament to the tremendous promise and commercial potential of the research we have jointly undertaken with Illinois.”
1. Source: Overview for SMi's 7th annual Point of Care Diagnostics: Market Adoption and Technology Trends conference; http://www.smi-online.co.uk/events/overview.asp?is=4&ref=3452
Ivan Yap Industry Development | Marketing and Communications Institute of Microelectronics, Singapore Email: yapsli@ime.a-star.edu.sg DID: (65) 6770 5375
11, Science Park Road, Singapore Science Park II, Singapore 117685 Website: http://www.ime.a-star.edu.sg